SCHEMBL4241303

SCHEMBL4241303

Cc1cc(-c2nc3ccccc3c(=O)n2NCc2ccc(Cl)cc2)ccc1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
KMT2A Q03164 2/20 0.55
MEN1 O00255 1/20 0.55
POLB P06746 1/20 0.55
MAPT P10636 6/20 0.53
NPSR1 Q6W5P4 4/20 0.53
LMNA P02545 3/20 0.53
HTT P42858 3/20 0.53
SMN1; SMN2 Q16637 5/20 0.52
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
CYP2D6 P10635 2/20 0.51
CYP2C9 P11712 2/20 0.51
CYP2C19 P33261 2/20 0.51
HPGD P15428 3/20 0.49
GAA P10253 2/20 0.47
TSHR P16473 2/20 0.46
KDM4E B2RXH2 2/20 0.46
MAPK1 P28482 1/20 0.46
EGFR P00533 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4242350 0.91 MAPT (0.55) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL4238083 0.89 ALDH1A1 (0.56) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL4240578 0.88 POLB (0.64) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL4242390 0.88 ALDH1A1 (0.62) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL4233225 0.88 SMN1; SMN2 (0.56) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL4237651 0.87 SMN1; SMN2 (0.67) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL4239831 0.85 POLB (0.65) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL4233360 0.85 ALDH1A1 (0.61) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL4237208 0.84 KMT2A (0.74) ALDH1A1KMT2AMEN1POLBMAPT
SCHEMBL4242316 0.83 MAPT (0.55) ALDH1A1KMT2AMEN1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 ALDH1A1 3192/4885KMT2A 4183/4885MEN1 4781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.